GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...
COLD SORES HAVE a way of appearing at the worst possible moments, like right before a big work presentation or a family ...
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
Brian Thompson, the CEO of UnitedHealth's insurance unit, was fatally shot in midtown Manhattan last week in what police ...
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...
Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty ...
1don MSN
The arrest in the slaying of UnitedHealthcare CEO Brian Thompson was the first step to putting his alleged killer behind bars ...
The global attenuated vaccines market is on track to achieve significant growth, with revenues projected to rise from USD ...
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback